Combining Immunotherapy and Targeted Therapies in Cancer Treatment

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2012 Mar 23

PMID 22437869

Citations 663

Authors

Matthew Vanneman

Glenn Dranoff

Affiliations

Soon will be listed here.

Abstract

During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer chemotherapies were initially identified through screens for compounds that killed rapidly dividing cells. These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance. More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Targeted approaches aim to inhibit molecular pathways that are crucial for tumour growth and maintenance; whereas, immunotherapy endeavours to stimulate a host immune response that effectuates long-lived tumour destruction. Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clinical outcomes.

Citing Articles

Chito-oligosaccharide impairs the proliferation, invasion and migration of pancreatic cancer cells.

Liu H, Ding S, Lyu W, Lu S, Liu X Discov Oncol. 2025; 16(1):298.

PMID: 40069446 PMC: 11896950. DOI: 10.1007/s12672-025-02015-2.

Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system.

Koylu B, Esen B, Bektas S, Ozbek L, Turan V, Urman B Sci Rep. 2025; 15(1):7770.

PMID: 40044844 PMC: 11883018. DOI: 10.1038/s41598-025-91476-0.

Light-based technologies in immunotherapy: advances, mechanisms and applications.

Frumento D, talu S Immunotherapy. 2025; 17(2):123-131.

PMID: 40032620 PMC: 11901425. DOI: 10.1080/1750743X.2025.2470111.

Immune Cell Homing Hydrogels for Cancer Immunotherapy.

Han J, Wang H Methods Mol Biol. 2025; 2902:107-116.

PMID: 40029598 DOI: 10.1007/978-1-0716-4402-7_6.

Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies.

Chand T, Dubey A, Misra G Heliyon. 2025; 11(3):e42437.

PMID: 40007779 PMC: 11850150. DOI: 10.1016/j.heliyon.2025.e42437.

References

Lee H, Pal S, Reckamp K, Figlin R, Yu H . STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2010; 344:41-59. PMC: 3244828. DOI: 10.1007/82_2010_51. View

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

Bekaii-Saab T, Roda J, Guenterberg K, Ramaswamy B, Young D, Ferketich A . A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009; 8(11):2983-91. PMC: 2996611. DOI: 10.1158/1535-7163.MCT-09-0820. View

Schmid M, Avraamides C, Dippold H, Franco I, Foubert P, Ellies L . Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19(6):715-27. PMC: 3144144. DOI: 10.1016/j.ccr.2011.04.016. View

Feng X, Yan J, Wang Y, Zierath J, Nordenskjold M, Henter J . The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol. 2010; 47(14):2388-96. DOI: 10.1016/j.molimm.2010.05.003. View

Benson Jr D, Bakan C, Zhang S, Collins S, Liang J, Srivastava S . IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011; 118(24):6387-91. PMC: 3490103. DOI: 10.1182/blood-2011-06-360255. View

Dranoff G . Experimental mouse tumour models: what can be learnt about human cancer immunology?. Nat Rev Immunol. 2011; 12(1):61-6. DOI: 10.1038/nri3129. View

Procaccini C, De Rosa V, Galgani M, Abanni L, Cali G, Porcellini A . An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity. 2010; 33(6):929-41. PMC: 3133602. DOI: 10.1016/j.immuni.2010.11.024. View

10.

Skov S, Pedersen M, Andresen L, Straten P, Woetmann A, Odum N . Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005; 65(23):11136-45. DOI: 10.1158/0008-5472.CAN-05-0599. View

11.

Haber D, Gray N, Baselga J . The evolving war on cancer. Cell. 2011; 145(1):19-24. DOI: 10.1016/j.cell.2011.03.026. View

12.

Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg A, Sebti S . Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol. 2005; 175(7):4338-46. PMC: 1351251. DOI: 10.4049/jimmunol.175.7.4338. View

13.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J . Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100(7):1111-9. PMC: 2670006. DOI: 10.1038/sj.bjc.6604965. View

14.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605):2103-11. DOI: 10.1016/S0140-6736(07)61904-7. View

15.

Balachandran V, Cavnar M, Zeng S, Bamboat Z, Ocuin L, Obaid H . Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011; 17(9):1094-100. PMC: 3278279. DOI: 10.1038/nm.2438. View

16.

Pander J, Heusinkveld M, der Straaten T, Jordanova E, Baak-Pablo R, Gelderblom H . Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res. 2011; 17(17):5668-73. DOI: 10.1158/1078-0432.CCR-11-0239. View

17.

Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S, Ricci V . Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology. 2011; 79(3-4):187-96. DOI: 10.1159/000320609. View

18.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

19.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View

20.

Herman S, Lapalombella R, Gordon A, Ramanunni A, Blum K, Jones J . The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011; 117(16):4323-7. PMC: 3087482. DOI: 10.1182/blood-2010-11-315705. View